On October 6, 2022 Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX System powered by Nano-Pulse Stimulation (NPS) technology, reported positive clinical data from an FDA approved Investigational Device Exempt treat and resect study on the use of NPS for low-risk basal cell carcinoma (BCC) lesions (Press release, Pulse Biosciences, OCT 6, 2022, View Source [SID1234621792]). An oral video presentation on the favorable results of performing the CellFX procedure for low-risk superficial and nodular BCC lesion clearance will be delivered at the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting, taking place on October 6-10, 2022 in Denver, Colorado.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"It is exciting and encouraging to see complete clearance of basal cell carcinoma lesions using NPS technology," said Amy Ross, MD, medical director and founder of PHDermatology of Tampa, Florida, and study investigator. "The results shown in this study gives me a high degree of confidence in NPS technology as an effective and cosmetically acceptable treatment, and potential alternative to the current standard of care for these types of BCC lesions."
Excisional surgery using electrodesiccation and curettage (ED&C) or Mohs micrographic surgery are the current standards of care for BCC lesions, both of which inevitably lead to scarring. Basal Cell Carcinoma is the most common form of skin cancer, accounting for 67% of all skin cancers and affecting more than 3.6 million patients annually. Nonsurgical NPS technology can potentially be a disruptive treatment option, due to its nonthermal energy to clear lesions with lower likelihood of scar formation.
"Showcasing this exciting new clinical data to dermatology thought leaders at ASDS is a major step towards demonstrating the applicability of NPS technology beyond benign dermatologic conditions," said Kevin Danahy, President and Chief Executive Officer of Pulse Biosciences. "The ongoing body of clinical evidence in dermatology continues to prove that NPS technology is safe and effective and produces excellent outcomes."
Oral Video Presentation:
Title: Nano-Pulse Stimulation (NPS) Technology for Treatment of Low-Risk Basal Cell Carcinoma (BCC) – Feasibility Study Using a Treat and Resect Design
Presented by: Dr. Amy Ross, Tampa, FL
Co-Authors: Amy S. Ross, MD; Todd Schlesinger, MD; Christopher Harmon, MD; Ronald Moy, MD; Thomas E. Rohrer, MD; Darius R. Mehregan, MD, PhD; Lauren M. Johnston, BS; William A. Knape, BS
Location: The video presentation will be available within the Education Session Room to those attending the 2022 American Society for Dermatologic Surgery (ASDS) Annual Meeting during open exhibit hours.